Skip to main content
S&P 5007,816.48+0.66%DOW51,754.40+1.02%NASDAQ27,371.10+0.65%BTC$82,377.00+1.02%ETH$2,481.03+1.17%GOLD$4,223.60+1.60%OIL$91.04-0.49%
Smart Investors Daily
SID Premium
EM

NASDAQ · EMBCV

Embecta Corp.

Healthcare · Drug Manufacturers - Specialty & Generic

$33.33

Down-$3.43 (-9.33%)

Updated Oct 9, 2026, 7:09 PM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.91B
P/E ratio
7.38
Dividend yield
0.00%
52-week range
— – —
Volume
132.3K
Avg. volume
3.48M

Price performance · EMBCV

EMBCV price history

1M range · 0 trading sessions · Daily adjusted prices

EMBCV does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest EMBCV news

The latest Smart Investors Daily articles mentioning EMBCV.

Stock researchCompany · Overview

EMBCV research

Overview

Company profile and research snapshot.

Company profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$36.00
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

seekingalpha.com · Nov 29, 2025

Embecta Growth Stalls Despite Strong Fiscal 2025 Results (Rating Downgrade)

Embecta Corp. (EMBC) faces a challenging fiscal 2026, with flat revenue and earnings growth expected - after a strong fiscal 2025. EMBC's weak outlook is driven by cannula costs, modest volume declines, and higher R&D expenses, despite improved margins and debt reduction. The dividend yield of 4.77% may appeal to income investors, but near-term growth prospects remain limited, warranting a Hold rating.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By